The New Era of Virus-Like Particles Based Vaccines
|The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Qatar|
|*Corresponding Author :||Mona Mohsen
The Jenner Institute, Nuffield Department of Medicine
University of Oxford, Qatar.
Tel: +44 (0)1865 617600
E-mail: [email protected]
|Received: March 02, 2016 Accepted: March 03, 2016 Published: March 05, 2016|
|Citation: Mohsen M (2016) The New Era of Virus-Like Particles Based Vaccines. Gene Technol 5:136. doi: 10.4172/2329-6682.1000136|
|Copyright: © 2016 Mohsen M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Virus-like particles or what is called VLPs for short are considered a useful tool in the development of vaccines. These VLPs-based vaccines have attracted the attention of many biotech and pharmaceutical companies as effective treatment for many types of non-infectious chronic diseases. VLPs simply resemble viruses; however they are noninfectious due to the lack of viral genome. The expression of envelop or capsid proteins result in the self-assembly of the particle, this assembly can easily be carried out in bacteria, yeast, plant cells or insect cell lines. The presence of repetitive viral surface protein epitopes is successful in eliciting strong B cell responses. VLPs have also high safety profile due to the lack of viral genome and lack of the ability to replicate. This area of research is not really new, the discovery of hepatitis B virus derived VLPs goes back to 1976.